- Home
- DHIL vs NMRA Comparison
DHIL vs NMRA Comparison
Compare DHIL & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | DHIL | NMRA |
|---|---|---|
| Founded | 1990 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.8M | 554.0M |
| IPO Year | 1996 | 2023 |
Fundamental Metrics
Financial Performance| Metric | DHIL | NMRA |
|---|---|---|
| Price | $174.99 | $1.84 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 26.3K | ★ 1.4M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.43% | N/A |
| EPS Growth | ★ 14.37 | 5.23 |
| EPS | ★ 17.91 | N/A |
| Revenue | ★ $145,201,729.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.77 | ★ N/A |
| Revenue Growth | ★ 6.69 | N/A |
| 52 Week Low | $114.11 | $0.66 |
| 52 Week High | $175.00 | $3.65 |
Technical Indicators
Market Signals| Indicator | DHIL | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 70.47 | 43.45 |
| Support Level | $171.71 | $1.81 |
| Resistance Level | N/A | $1.90 |
| Average True Range (ATR) | 0.60 | 0.18 |
| MACD | 0.25 | -0.01 |
| Stochastic Oscillator | 99.72 | 26.32 |
Price Performance
Historical ComparisonAbout DHIL Diamond Hill Investment Group Inc.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.